Clinical trials: Locally Advanced Non-Small Cell Lung Cancer, open to volunteers
Non-Small Cell Lung Cancer
Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study
Research objective: To evaluate the efficacy and safety of gematinib combined with lenvatinib in the treatment of advanced or metastatic NSCLC with MET overexpression that has failed standard therapy Experimental design…
- Trial name
- NCT07894367
- Testing
- Gematinib, Lenvatinib
- Volunteers
- 23 people
- Sponsor
- Peking University Cancer Hospital & Institute
Stage III Non-small Cell Lung Cancer, Locally Advanced
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Multinational, randomized, controlled, open-label, multicenter phase II trial. Eligible patients will be randomized in a ratio of 1:1 to Experimental Arm (FDG-PET-based small volume accelerated radiotherapy with concurrent…
- Conditions
- Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
- Trial name
- PACCELIO (NCT06102057)
- Testing
- standard Radiotherapy, Chemotherapy, Immunotherapy
- Where
- 11 sites in Germany, Switzerland
- Volunteers
- 110 people
- Sponsor
- TheraOp
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Advanced or Metastatic Non-small Cell Lung Cancer
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with…
- Trial name
- NCT07170995
- Testing
- SHR-8068，adebelizumab and platinum-based chemotherapy, tislelizumab, and platinum-based chemotherapy
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Non-Small Cell Lung Cancer
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC.
- Trial name
- LIBRA (NCT07098338)
- Testing
- Rilvegostomig, Ramucirumab, Dato-DXd
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 278 people
- Sponsor
- AstraZeneca
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and…
- Trial name
- REZILIENT2 (NCT05967689)
- Testing
- TAS6417, CYP Cocktail, Transporter Cocktail
- Where
- 80 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- Taiho Oncology, Inc.
Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
- Conditions
- Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
- Trial name
- NCT07857616
- Testing
- SI-B036
- Where
- 7 sites in United States
- Volunteers
- 424 people
- Sponsor
- SystImmune Inc.
Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced…
- Conditions
- Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
- Trial name
- NCT07632365
- Testing
- Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shanghai Chest Hospital
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06066138
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose…
- Trial name
- NCT06868485
- Testing
- WSD0922-FU Tablets, Dose level A, WSD0922-FU Tablets, Dose level B
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 40 people
- Sponsor
- Wayshine Biopharm, Inc.
Non Small Cell Lung Cancer
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
This is a multicenter, randomized, open-label, non-inferiority real world study. The study is designed to evaluate the efficacy and safety of Aumolertinib versus Osimertinib in the first-line treatment of patients with EGFR…
- Trial name
- ANOTHER (NCT06752408)
- Testing
- Aumolertinib, Osimertinib
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
This is a Phase II study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212 in combination with JS111 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring…
- Trial name
- NCT07518160
- Testing
- JS212 for Injection＋JS111 capsules (AP-L1898)
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.